Highlights
So, to most of the patients we’re giving Eylea at the moment, which is aflibercept, and this may be the gold standard at the beginning of the treatment.
How I see things and probably what’s going to happen is we’re going to begin working with combinations. This is how I personally think the market is going to move. Why? Because going for new targets is going to be much more difficult, much more expensive, and I think wet AMD is different for example from diabetic macular edema, the goal is different.
I think the delivery system is a very, very good idea. So, I can imagine that maybe in the next five years we’re going to have one or two changes in terms of how the delivery system works. I can imagine it will be easier to inject. […] Instead of Lucentis, maybe we’re going to use other drugs, or, like you said, a combination of drugs. But I think the PDS is going to last, it’s going to stay.
Overview
A Spain-based KOL opines about the most used agents in wet AMD with particular emphasis on the effect of cost and safety in making prescribing decisions. During the discussion, the KOL gives a glimpse of what the future might hold in terms of newer agents and combination therapy. The KOL also speaks about novel modes of administration and the impact of these on the current market.